(Q46675071)

24 December 2017

title

Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia (English)

1 reference

24 December 2017

1 reference

1 reference

ter Avest E

1

1 reference

24 December 2017

Abbink EJ

2

1 reference

24 December 2017

de Graaf J

3

1 reference

24 December 2017

Tack CJ

4

1 reference

24 December 2017

Stalenhoef AF

5

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

European Journal of Clinical Investigation

published in

1 reference

24 December 2017

volume

35

1 reference

24 December 2017

issue

9

1 reference

24 December 2017

page(s)

558-564

1 reference

24 December 2017

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Defects of lipoprotein metabolism in familial combined hyperlipidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Clinical implications of insulin resistance syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2005.01549.X

10.1111/J.1365-2362.2005.01549.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16128862

1 reference

24 December 2017